BIOMARKERS TO PREDICT RESPONSE TO IMMUNE CHECKPOINT INHIBITOR THERAPY IN CANCER

BIOMARKERS TO PREDICT RESPONSE TO IMMUNE CHECKPOINT INHIBITOR THERAPY IN CANCER
Author(s):
Kriti Jain, Shyam Aggarwal, Surajit Ganguly, Nirmal Kumar Ganguly, Amit Awasthi, Deepa Mehra
Keywords:
Immune checkpoint inhibitors, PD1/PD-L1, CTLA4, biomarkers, immunotherapy, solid tumors, predictive biomarkers
Abstract
Traditional treatment modalities for advanced cancer act directly on tumors to inhibit growth or destroy them. Along with surgery, these modalities are predominantly palliative, though associated with toxicity and modest improvements in survival of patients with advanced solid tumors. To address these issues, novel immunotherapies targeting programmed death-1 (PD-1/PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA4) have been developed and approved by the FDA. These therapies have been proven to provide substantial benefit and success in advanced solid tumors of different types. However, these expensive checkpoint inhibitor therapies extend clinical benefits to only a small subset of patients. Hence, it is crucial to comprehend the determinants and the role of biomarkers that drive response, resistance, and adverse effects. In this review, we have elaborated on the role of various biomarkers both pre-treatment and post-treatment which assist in predicting response to immune checkpoint inhibitors in cancer treatment.
Article Details
Unique Paper ID: 156858 Publication Volume & Issue: Volume 9, Issue 5 Page(s): 205 - 221
Article Preview & Download

Share This Article

NCSST-2021

AICTE Sponsored National Conference on Smart Systems and Technologies

Last Date: 25th November 2021

LATEST INNOVATION’S AND FUTURE TRENDS IN MANAGEMENT

Last Date: 7th November 2021